Pen Needle Market Size, Share, Opportunities, And Trends By Type (Standard Pen Needles, Safety Pen Needles), By Length (4mm and 5mm, 6mm and 8mm, 10mm and 12mm), By Therapy (Insulin, Glucagon-like-Peptide-1, Growth Hormone), By Distribution Channel (Online, Offline), And By Geography - Forecasts From 2025 To 2030

The pen needle market is expected to grow at a CAGR of 9.27% over the forecast period to reach a total market size of US$3,189.0.12 million by 2030, increasing from US$2,046.792 million in 2025. 

Pen needles are widely used to deliver injectable medication into the body. The growing prevalence of chronic disease is expected to be one of the prime drivers of market growth during the forecast period. However, the availability of substitutes is anticipated to restrain the market's growth in the coming years.

What are the Pen Needle Market drivers?

• The growing prevalence of various chronic diseases is anticipated to drive the market in the forecasted period

The rising prevalence of chronic diseases such as cancer and diabetes is one of the prime drivers for market growth during the forecast period. According to the International Diabetes Federation report, the number of people with diabetes under the age group of 20-79 years has risen from 425 million in 2017 to 537 million in 2022. It is expected to reach 783 million in 2045.

In addition, the rising economic burden of diabetes and increasing healthcare expenditure worldwide are also anticipated to increase the demand for rapid diagnostic kits for glucose monitoring in the coming years. According to the International Diabetes Federation (IDF), global healthcare expenditure on diabetes was around USD 966 billion in 2022, representing an increase of 316% over the last 15 years. 

According to the World Health Organization (WHO), in 2022, nearly 1.3 million people died from chronic hepatitis B and C infection; approximately 254 million people are living with hepatitis B, and 50 million people are living with hepatitis C. The WHO also stated that in 2010, an estimated 524 million people were aged 65 or older, constituting 8% of the world’s population. By 2050, this number is expected to nearly triple to about 1.5 billion, representing 16% of the world population.

Poor nutrition, physical inactivity, and the harmful use of alcohol contribute to the development of chronic conditions like cardiovascular diseases, cancer, and chronic respiratory disease, directly impacting the market for pen needles in the coming years.

• The rising aging population is anticipated to fuel the market for pen needles in the projected period

One of the main factors driving the market's expansion over the forecast period is anticipated to be the growing elderly population in several regions of the world. For instance, based only on the rising geriatric population in a developing country like China, the WHO has predicted a 50% increase in annual cardiovascular disease occurrences between 2010 and 2030. 

According to the World Bank, the population aged sixty-five and above in Europe was 448.8 million, making one-fifth of the total population of 21.3% in 2023, in Europe. In addition, rising disposable income encourages people to demand better quality healthcare solutions for which they are ready to pay high premiums. The surging need for private health insurance plans is also increasing the number of surgical procedures in this country.

Segment analysis of Pen Needle Market:

• The insulin therapy segment is anticipated to hold a significant market share in the projected period

The pen needle market is divided by therapy into insulin, glucagon-like peptide-1 (GLP-1), and growth hormone administration, driven by the increasing prevalence of chronic conditions and rising demand for self-injection devices. Insulin therapy held the largest share, mainly because of the increasing diabetic population and widespread use of insulin pens for ease and accuracy in self-administration.

The GLP-1 segment is highly growth-positive and has achieved immense success in treating type 2 diabetes and weight-related disorders. As a result, demand for pen needles compatible with the drugs is rising. Growth hormone therapy also adds to the market significantly, particularly for pediatric and adult patients requiring hormone replacement, where the use of pen needles is less invasive and more patient-friendly. Advances in the design of pen needles, such as ultra-thin, short needles, are driving market expansion for all therapeutic segments.

Geographical outlook of the Pen Needle Market:

• North America will continue to hold a remarkable market share during the forecast period

By geography, the pen needle market is segmented into North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The pen needle is fast gaining traction in North America due to the growing number of chronic disease cases. According to the United States Centre for Disease Control and Prevention, 6,08,336 people died due to cancer in the United States. The burgeoning need for a targeted drug delivery system that causes minimal side effects drives the demand for pen needles in the country.

Advancements in technology and increased healthcare spending have significantly boosted the pen needle market growth. For instance, U.S. healthcare spending increased by 4.1% to reach USD 4.5 trillion in 2022, as per the United States Centre for Medicare and Medicaid Services.

In the European region, to address the growing needs of the aging population, the government is easing regulations and accelerating approval of the innovative new drug in a campaign to promote pharmaceutical companies, both domestic and foreign, and to attract new companies to the European market. In addition, increasing strategic investment by domestic market players in the form of mergers and acquisitions increases the competition, further propelling market growth in the coming years.

Furthermore, in the Asia Pacific region, increasing health awareness among the population and the market's rapid evolution in using new injectable drug delivery systems or technologies are driving market growth during the forecast period. The Chinese and Indian governments are trying to establish new policies to improve the population's health, including coverage expansion of public healthcare institutions and standardizing the services they offer.

Key developments in the Pen Needle Market:

• In November 2024, Evergreen Medical launched evercare® pen needles, a new benchmark for comfort and safety in treating type I diabetes. The new pen needles are specifically designed for insulin pens, promising an elevated experience by prioritizing comfort and risk reduction. Conceived with patient needs, evercare® Pen Needles represent a significant leap forward in diabetes care and provide a better solution for effective and safe insulin administration.

Pen Needle Market Scope:

Report Metric	Details
Pen Needle Market Size in 2025	US$2,046.792 million
Pen Needle Market Size in 2030	US$3,189.0.12 million
Growth Rate	CAGR of 9.27%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Million
Segmentation	Type Length Therapy Distribution Channel Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Pen Needle Market	Becton, Dickinson and Company Glucorx Braun Melsungen Ypsomed Novo Nordisk
Customization Scope	Free report customization with purchase

 

The Pen Needle Market is analyzed into the following segments:

• By Type
  • Standard Pen Needles
  • Safety Pen Needles
• By Length
  • 4mm and 5mm
  • 6mm and 8mm
  • 10mm and 12mm
• By Therapy
  • Insulin 
  • Glucagon-like-Peptide-1
  • Growth Hormone
• By Distribution Channel
  • Online
  • Offline
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Italy
    • Others
  • Middle East and Africa
    • UAE
    • Saudi Arabia
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.1.1. Growing Demand for Packaging

4.1.2. Increasing Focus on Sustainability

4.2. Market Restraints

4.2.1. Environmental Concerns

4.2.2. High Production Cost

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. The Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

 

5. PEN NEEDLE MARKET BY TYPE

5.1. Introduction

5.2. Standard Pen Needles

5.3. Safety Pen Needles

6. PEN NEEDLE MARKET BY LENGTH

6.1. Introduction

6.2. 4mm and 5mm

6.3. 6mm and 8mm

6.4. 10mm and 12mm

7. PEN NEEDLE MARKET BY THERAPY

7.1. Introduction

7.2. Insulin 

7.3. Glucagon-like-Peptide-1

7.4. Growth Hormone

8. PEN NEEDLE MARKET BY DISTRIBUTION CHANNEL

8.1. Introduction

8.2. Online

8.3. Offline

9. PEN NEEDLE MARKET BY GEOGRAPHY

9.1. Introduction

9.2. North America 

9.2.1. United States 

9.2.2. Canada 

9.2.3. Mexico 

9.3. South America 

9.3.1. Brazil 

9.3.2. Argentina 

9.3.3. Others

9.4. Europe 

9.4.1. UK 

9.4.2. Germany 

9.4.3. France 

9.4.4. Spain 

9.4.5. Italy 

9.4.6. Others

9.5. Middle East and Africa 

9.5.1. UAE 

9.5.2. Saudi Arabia 

9.5.3. Others

9.6. Asia Pacific 

9.6.1. Japan 

9.6.2. China 

9.6.3. India 

9.6.4. South Korea 

9.6.5. Indonesia 

9.6.6. Thailand 

9.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix

11. COMPANY PROFILES

11.1. Becton, Dickinson and Company 

11.2. Glucorx 

11.3. Braun Melsungen 

11.4. Ypsomed 

11.5. Novo Nordisk 

11.6. HTL-Strefa 

11.7. Ultimed, Inc. 

11.8. Allison Medical, Inc.  

11.9. Terumo Corporation 

11.10. Owen Mumford, Ltd.  

Becton, Dickinson and Company

Glucorx

Braun Melsungen

Ypsomed

Novo Nordisk

HTL-Strefa

Ultimed, Inc.

Allison Medical, Inc. 

Terumo Corporation

Owen Mumford, Ltd.